What we do Indoco Remedies Ltd is a Mumbai-based pharmaceutical company specializing in manufacturing and marketing formulations and Active Pharmaceutical Ingredients, serving over 55 countries globally. |
Founded in 1,947 |
Market share Ranks 34th in Indian pharma industry, with leading positions in stomatology, ophthalmic, and pediatric segments. |
Problem solved Provides high-quality pharmaceutical formulations and APIs addressing therapeutic needs including anti-infective, cardiovascular, diabetic, and lifestyle diseases. |
Top clients or who we serve Serves hospitals, clinics, and healthcare providers globally; primarily B2B with prescription segments domestically. |
Key management - |
Our journey and innovations Established in 1947, expanded globally with 11 manufacturing units, acquired clinical research facilities, secured multiple patents, and launched super specialty divisions. |
Where we operate India, Europe, United States and over 55 countries worldwide through subsidiaries and export markets. |
Top products or what we offer Pharmaceutical formulations across anti-infective, ophthalmic, anti-inflammatory, and lifestyle segments; contract manufacturing and clinical research services. |
Top brands Naricover, Dropizin Syrup, Methycal 60 K, Rexidin SRS among others in acute, chronic and sub-chronic categories. |
Raw materials needed Active pharmaceutical ingredients, excipients, chemical compounds used in drug formulations and manufacturing. |
Raw materials supplier Not specified in available data. |
Recurring vs cyclical contribution Revenue largely from recurring sales of pharmaceutical formulations with intermittent research and contract manufacturing income. |
Our industry position Mid-sized pharma with strong niche presence domestically; continually expanding specialty portfolios and geographical footprint. |
Financial highlights FY25 consolidated revenue Rs.1665 crore; net loss Rs.74 crore; Dividend declared at Rs.0.20 per share; Revenue decline due to market conditions. |
Geographical revenue split Approximately Rs.1090 crore from India and Rs.551 crore from international markets in FY25. |
Order book - |
Whats driving growth Expansion in specialty divisions, R&D investments, new product launches, global acquisitions, and enhanced clinical research capabilities. |
Our future plans Increase manufacturing capacity via Warren Remedies, expand US and European markets through subsidiaries, and invest in renewable energy projects. |
Our green promise Investments in solar power plants through associate companies to promote sustainability. |
Our people and values Strong emphasis on employee stock ownership, ethical practices, and a culture fostering innovation and compliance. |
Key challenges ahead Managing profitability amidst market pressures, regulatory compliances, and competition in domestic and international pharma sectors. |
Interesting facts Has received multiple patents and awards; acquired clinical research division to reduce outsourcing; operates certified facilities as per US FDA and UK MHRA norms. |
Risks and strategy Faces risks from regulatory changes and market volatility; mitigates through R&D, diversification, compliance policies, and geographic expansion. |
